Program
Anti-GFRAL Monoclonal Antibody NGM120
Also written as “NGM120 Q4W”, “NGM120 Q8W” and “NGM120 30mg”.
Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Cachexia, led by NGM Biopharmaceuticals.
Drug pageAnti-GFRAL Monoclonal Antibody NGM120: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NGM Biopharmaceuticals | 31 open or running | phase 2since Aug 22, 2019 | Dec 8, 2017 | Apr 2027phase 2 · NCT07033026 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 8, 2017First study: phase 1 study in CachexiaFirst studyNCT03392116 · 92 enrolled · Australia
- Aug 22, 2019Phase 2 study in Pancreatic NeoplasmsNCT04068896 · 89 enrolled · United States
- Jun 13, 2025Phase 2 study in Colorectal NeoplasmsNCT07033026 · 136 planned · United States, Georgia, South Korea and more
Ahead
- Apr 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07033026
TargetBeta
“A long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07033026Colorectal Neoplasms · United States, Georgia, South Korea and more | 2 | Recruiting | Apr 2027 | 136 |
| NCT04068896Pancreatic Neoplasms · United States | 2 | Completed | Sep 21, 2023 | 89 |
| NCT03392116Cachexia · Australia | 1 | Completed | Jan 14, 2019 | 92 |
How it is read
Names in the registry
- “NGM120 Q4W”, 1 entry
- “NGM120 Q8W”, 1 entry
- “NGM120 30mg”, 1 entry
- “NGM120 100mg”, 1 entry
- “NGM120 30mg with Gemcitabine and Abraxane”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
- Cachexia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.